At a glance
- Originator Pierre Fabre
- Class Nootropics
- Mechanism of Action Alpha-2 adrenergic receptor inverse agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Alzheimer's disease; Parkinson's disease
Most Recent Events
- 02 Dec 2003 Preclinical trials in Parkinson's disease in France (unspecified route)
- 02 Dec 2003 Preclinical trials in Alzheimer's disease in France (unspecified route)